GT Biopharma (GTBP) Stock Price, News & Analysis

Company Overview

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biopharmaceutical company focused on the development of innovative natural killer (NK) cell engager therapies for the treatment of cancer. The company’s proprietary pipeline centers on Bispecific and Trispecific Killer Engagers (BiKE® and TriKE®) designed to harness and enhance the body’s innate immune system by directing NK cells to recognize and kill tumor cells. GT Biopharma is advancing its lead candidate, GTB-3550, a TriKE targeting CD33-positive hematologic malignancies, through Phase 1/2 clinical trials in patients with acute myeloid leukemia (AML) and other myeloid disorders.

Founded in 2008 and headquartered in Houston, Texas, GT Biopharma has built a robust preclinical and clinical portfolio that leverages expertise in antibody engineering and cell therapy. In addition to GTB-3550, the company is developing next-generation TriKE constructs aimed at solid tumors, including molecules that target antigens such as HER2 and EGFR. These programs are positioned to address significant unmet medical needs by offering off-the-shelf immunotherapy options without the complexity or cost associated with patient-specific cell manufacturing.

GT Biopharma operates a centralized research and manufacturing facility in Houston, which supports both discovery and scale-up activities. The company collaborates with academic institutions and contract research organizations across North America to accelerate clinical development and optimize manufacturing processes. GT Biopharma’s approach emphasizes modular design, enabling rapid adaptation of its engager platform to emerging tumor targets and combination strategies with existing immunotherapies.

The leadership team is spearheaded by President and CEO Alan J. Lewis, whose background spans oncology drug development and strategic licensing partnerships. Under his guidance, GT Biopharma has expanded its executive ranks and board of directors to include industry veterans with extensive experience in immuno-oncology, clinical operations, and regulatory affairs. Together, the team is focused on advancing the company’s clinical candidates through pivotal studies with the goal of delivering transformative therapies to cancer patients worldwide.

Key Stats

• Today's Range: $2.22 to $2.31
• 50-Day Range: $2.05 to $3.80
• 52-Week Range: $1.72 to $4.10
• Volume: 62,313 shs
• Average Volume: 250,147 shs
• Market Capitalization: $7.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Strong Buy

GT Biopharma Stock Analysis - MarketRank™

GT Biopharma scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

GT Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GT Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GT Biopharma are expected to grow in the coming year, from ($6.79) to ($2.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GT Biopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GT Biopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.48% of the float of GT Biopharma has been sold short.

Short Interest Ratio / Days to Cover

GT Biopharma has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in GT Biopharma has recently increased by 40.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GT Biopharma does not currently pay a dividend.

Dividend Growth

GT Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.48% of the float of GT Biopharma has been sold short.

Short Interest Ratio / Days to Cover

GT Biopharma has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in GT Biopharma has recently increased by 40.25%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

GT Biopharma has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for GT Biopharma this week, compared to 0 articles on an average week.

MarketBeat Follows

3 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GT Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.40% of the stock of GT Biopharma is held by insiders.

Percentage Held by Institutions

Only 8.15% of the stock of GT Biopharma is held by institutions.

GTBP Stock Analysis - Frequently Asked Questions

How have GTBP shares performed this year?

GT Biopharma's stock was trading at $3.05 at the beginning of 2025. Since then, GTBP stock has decreased by 26.9% and is now trading at $2.23.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12.

When did GT Biopharma's stock split?

GT Biopharma shares reverse split on Monday, February 5th 2024.The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of GT Biopharma?

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GTBP
• Previous Symbol: OTCMKTS:OXISD
• CIK: 109657
• Web: www.gtbiopharma.com
• Phone: (415) 919-4040
• Fax: N/A
• Employees: 8
• Year Founded: 1965

Price Target and Rating

• Average Price Target for GT Biopharma: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +393.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,033.08%
• Return on Assets: -223.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.73
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.75) per share
• Price / Book: -2.97

Miscellaneous

• Outstanding Shares: 3,270,000
• Free Float: 3,162,000
• Market Cap: $7.29 million
• Optionable: No Data
• Beta: 1.48